Frances Alice Shepherd
#70,973
Most Influential Person Now
Canadian oncologist
Frances Alice Shepherd's AcademicInfluence.com Rankings
Frances Alice Shepherdphilosophy Degrees
Philosophy
#4432
World Rank
#6941
Historical Rank
Logic
#1882
World Rank
#2746
Historical Rank
Download Badge
Philosophy
Frances Alice Shepherd's Degrees
- Masters Oncology University of British Columbia
Why Is Frances Alice Shepherd Influential?
(Suggest an Edit or Addition)According to Wikipedia, Frances Alice Shepherd, is a Canadian oncologist recognized for her research on lung cancer and her contributions to the design, development, and conduct of clinical trials. She is currently a senior staff physician at Princess Margaret Cancer Centre, where she has held the Scott Taylor Chair in Lung Cancer Research since 2001, and she is a full professor in the Department of Medicine at the University of Toronto.
Frances Alice Shepherd's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Erlotinib in previously treated non-small-cell lung cancer. (2005) (4245)
- Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. (2004) (2399)
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer (2017) (2140)
- Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. (2000) (2127)
- Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. (2008) (1928)
- Erlotinib in lung cancer - molecular and clinical predictors of outcome. (2005) (1488)
- Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. (2005) (1409)
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial (2008) (1275)
- Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial (2009) (1199)
- Characterizing the cancer genome in lung adenocarcinoma (2007) (1122)
- Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study (2008) (1063)
- Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. (1999) (825)
- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. (2017) (765)
- Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. (2008) (717)
- The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. (2009) (694)
- Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. (2020) (590)
- Lung cancer susceptibility locus at 5p15.33 (2008) (562)
- Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. (2016) (506)
- Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. (2010) (497)
- Liquid Biopsy for Advanced Non‐Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC (2018) (445)
- The IASLC Lung Cancer Staging Project: Proposals Regarding the Relevance of TNM in the Pathologic Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer (2009) (440)
- Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. (2010) (437)
- Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. (2016) (414)
- Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. (1996) (412)
- The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the Tumor, Node, Metastasis Classification for Lung Cancer (2007) (411)
- Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. (2014) (400)
- Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. (2016) (380)
- EGFR mutations and lung cancer. (2011) (379)
- Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). (2007) (377)
- Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes (2017) (353)
- Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. (2010) (353)
- Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. (2005) (351)
- Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. (2004) (344)
- ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. (2013) (344)
- Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. (2015) (326)
- Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer (2020) (323)
- Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer (2011) (320)
- Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. (2007) (316)
- Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. (2006) (309)
- Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). (2017) (306)
- Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. (2008) (299)
- Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. (2000) (295)
- Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. (2001) (295)
- Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. (2013) (289)
- Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. (2002) (285)
- Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. (2003) (268)
- Non-small-cell lung cancer (2011) (268)
- Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). (2001) (265)
- Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. (2015) (263)
- Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. (2013) (262)
- Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer. (2016) (261)
- Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. (1996) (260)
- Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309) (2005) (255)
- A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial (2004) (246)
- Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. (2003) (245)
- Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. (2014) (239)
- Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. (2015) (238)
- Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer (2002) (238)
- Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer (2011) (225)
- Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. (2007) (223)
- Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. (2010) (221)
- Validation of a Histology-Independent Prognostic Gene Signature for Early-Stage, Non–Small-Cell Lung Cancer Including Stage IA Patients (2014) (221)
- K-ras mutations in non-small-cell lung carcinoma: a review. (2006) (219)
- Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. (1987) (218)
- Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. (2001) (214)
- EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. (2019) (213)
- Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection. (2015) (211)
- Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. (2008) (210)
- Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. (2017) (209)
- Molecular predictive and prognostic markers in non-small-cell lung cancer. (2009) (208)
- Prognostic gene signatures for non-small-cell lung cancer (2009) (206)
- Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non-Small-Cell Lung Cancer Guideline. (2007) (205)
- Three-gene prognostic classifier for early-stage non small-cell lung cancer. (2007) (205)
- Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer: Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation (2010) (199)
- Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial. (1992) (195)
- Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. (2005) (194)
- Acute leukemia during pregnancy: the Toronto Leukemia Study Group experience with long-term follow-up of children exposed in utero to chemotherapeutic agents. (1987) (194)
- Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. (2007) (192)
- Longitudinal study of depressive symptoms in patients with metastatic gastrointestinal and lung cancer. (2010) (190)
- Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial (2016) (188)
- Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer (2007) (186)
- CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials (2017) (185)
- Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. (1997) (182)
- Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data (2013) (182)
- Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. (2005) (181)
- Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. (2008) (179)
- Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. (2007) (173)
- Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer. (2014) (170)
- Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer. (2018) (168)
- Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients. (2006) (166)
- Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. (2012) (166)
- Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. (2006) (165)
- Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. (2005) (164)
- Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. (1999) (161)
- Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. (2009) (161)
- Twenty‐five years of clinical research for patients with limited‐stage small cell lung carcinoma in North America (2002) (161)
- The Ability to Form Primary Tumor Xenografts Is Predictive of Increased Risk of Disease Recurrence in Early-Stage Non–Small Cell Lung Cancer (2010) (158)
- Hepatocellular carcinoma: pilot trial of treatment with Y-90 microspheres. (1989) (156)
- Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. (2004) (154)
- Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. (2006) (152)
- The desire for hastened death in patients with metastatic cancer. (2007) (151)
- Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. (2009) (149)
- Class III β-Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non–Small Cell Lung Cancer: Analysis of NCIC JBR.10 (2007) (148)
- Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study. (2017) (144)
- Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first‐line therapy in patients with advanced nonsmall cell lung carcinoma (2001) (144)
- Influence of age on the treatment of limited-stage small-cell lung cancer. (1996) (143)
- Lymphoma of the gastrointestinal tract. (1999) (141)
- Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report (2019) (134)
- Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. (1999) (134)
- Nivolumab Plus Erlotinib in Patients With EGFR‐Mutant Advanced NSCLC (2018) (131)
- Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras. (1999) (130)
- Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). (2017) (129)
- Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature. (2005) (129)
- No association between hepatitis C and B‐cell lymphoma (1999) (128)
- Differential expression of matrix metalloproteinases and their inhibitors in non‐small cell lung cancer (2000) (128)
- Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. (2008) (119)
- A phase I dose escalation trial of yttrium‐90 microspheres in the treatment of primary hepatocellular carcinoma (1992) (119)
- Epidermal growth factor receptor inhibition in lung cancer: status 2012. (2013) (119)
- Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization. (2001) (118)
- Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. (2006) (115)
- Medical management of malignant pericardial effusion by tetracycline sclerosis. (1987) (114)
- Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies (2018) (113)
- Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. (2014) (113)
- Predictors of referral for specialized psychosocial oncology care in patients with metastatic cancer: the contributions of age, distress, and marital status. (2009) (112)
- Lung cancer screening using low-dose computed tomography in at-risk individuals: the Toronto experience. (2010) (112)
- Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group. (1998) (112)
- Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non–Small-Cell Lung Cancer Treated with Erlotinib or Placebo in the NCIC Clinical Trials Group BR.21 Trial (2012) (112)
- Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. (2003) (110)
- Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. (2006) (109)
- Pericardial sclerosis as the primary management of malignant pericardial effusion and cardiac tamponade. (1996) (108)
- A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10 (2004) (108)
- KIF14 Messenger RNA Expression Is Independently Prognostic for Outcome in Lung Cancer (2007) (108)
- The IASLC Lung Cancer Staging Project: Data Elements for the Prospective Project (2009) (108)
- First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status. (2014) (106)
- Treatment of Kaposi's sarcoma after solid organ transplantation. (1997) (106)
- Influence of sex on toxicity and treatment outcome in small-cell lung cancer. (2005) (105)
- Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer (2010) (104)
- Uncommon EGFR mutations in advanced non-small cell lung cancer. (2017) (103)
- KRAS Mutations as Prognostic and Predictive Markers in Non–Small Cell Lung Cancer (2013) (102)
- Novel candidate tumor marker genes for lung adenocarcinoma (2002) (101)
- The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit. (2010) (100)
- The Cost‐Effectiveness of High‐Risk Lung Cancer Screening and Drivers of Program Efficiency (2017) (99)
- Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. (2003) (99)
- A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer (2011) (98)
- Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. (2020) (97)
- Chemotherapy for Relapsed Small Cell Lung Cancer: A Systematic Review and Practice Guideline (2007) (97)
- The influence of age on the delivery, tolerance, and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. (1999) (96)
- Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer. (1997) (95)
- Prevention and Management of Bone Metastases in Lung Cancer: A Review (2009) (94)
- Clinical Utility of Epidermal Growth Factor Receptor Expression for Selecting Patients with Advanced Non-small Cell Lung Cancer for Treatment with Erlotinib (2006) (94)
- Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer (2006) (93)
- A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19. (2010) (91)
- PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer (2017) (91)
- Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. (2014) (91)
- Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer. (2009) (90)
- Neurologic disorders in patients with small cell lung cancer (1987) (90)
- Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC) (2014) (89)
- Ketoconazole in the management of paraneoplastic Cushing's syndrome secondary to ectopic adrenocorticotropin production. (1995) (89)
- Integrated Omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impact (2014) (89)
- Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. (2012) (88)
- Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD‐1 Axis Inhibitors in Patients With Advanced Non–Small‐Cell Lung Cancer (2018) (88)
- Prospective comparison of the sclerosing agents doxycycline and bleomycin for the primary management of malignant pericardial effusion and cardiac tamponade. (1996) (87)
- The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. (2010) (87)
- Extragonadal germ cell tumors. A 14‐year Toronto experience (1994) (85)
- Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma. (2015) (85)
- A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in Platinum- and Erlotinib-Resistant Adenocarcinoma of the Lung (2010) (84)
- Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. (2010) (83)
- Optimized application of penalized regression methods to diverse genomic data (2011) (82)
- Superior vena caval obstruction syndrome in small cell lung cancer (1986) (82)
- Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. (2007) (80)
- Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study. (1998) (80)
- Skp2 Gene Copy Number Aberrations Are Common in Non-Small Cell Lung Carcinoma, and Its Overexpression in Tumors with ras Mutation Is a Poor Prognostic Marker (2004) (79)
- Adjuvant chemotherapy for non-small-cell lung cancer in the elderly: a population-based study in Ontario, Canada. (2012) (79)
- Chemotherapy for elderly patients with non-small cell lung cancer: a review of the evidence. (2005) (78)
- CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. (2016) (78)
- A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. (2004) (78)
- Does the incidence and outcome of brain metastases in locally advanced non-small cell lung cancer justify prophylactic cranial irradiation or early detection? (2005) (77)
- Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. (2010) (77)
- Improved results of induction chemoradiation before surgical intervention for selected patients with stage IIIA-N2 non-small cell lung cancer. (2007) (76)
- Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer. (2002) (76)
- Prognostic and Predictive Effect of TP53 Mutations in Patients with Non–Small Cell Lung Cancer from Adjuvant Cisplatin–Based Therapy Randomized Trials: A LACE‐Bio Pooled Analysis (2016) (75)
- Randomized study of chemotherapy and surgery versus radiotherapy for stage IIIA non-small-cell lung cancer: a National Cancer Institute of Canada Clinical Trials Group Study. (1998) (75)
- Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations. (2006) (75)
- Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. (2017) (74)
- Economic issues in lung cancer: a review. (1998) (74)
- Tecemotide ( L-BLP 25 ) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer ( START ) : a randomised , double-blind , phase 3 trial (2013) (73)
- Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes (2009) (73)
- Second-Line Treatment of Advanced Non-small Cell Lung Cancer (2008) (73)
- Lung cancer risk in never-smokers: a population-based case-control study of epidemiologic risk factors (2010) (73)
- Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10. (2008) (72)
- ALK‐Rearranged Non–Small‐Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism (2017) (72)
- Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery. (1998) (72)
- Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer. (2005) (71)
- An Investigation of Nonhemolytic Transfusion Reactions (1984) (71)
- Co-expression of epidermal growth factor receptor and transforming growth factor-alpha is independent of ras mutations in lung adenocarcinoma. (2000) (71)
- Adoption of adjuvant chemotherapy for non-small-cell lung cancer: a population-based outcomes study. (2010) (68)
- Tissue Heterogeneity of EGFR Mutation in Lung Adenocarcinoma (2008) (68)
- Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer. (1997) (68)
- Screening for Malignant Pleural Mesothelioma and Lung Cancer in Individuals with a History of Asbestos Exposure (2009) (67)
- Detection of occult low‐grade B‐cell non‐hodgkin's lymphoma in patients with chronic hepatitis C infection and mixed cryoglobulinemia (1999) (67)
- Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy in Non-small Cell Lung Cancer (2011) (66)
- Chemotherapy for non-small cell lung cancer: have we reached a new plateau? (1999) (65)
- Lymphoproliferative disorders after liver transplantation: imaging features (2001) (64)
- Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. (2014) (64)
- KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy (2015) (63)
- Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21. (2010) (62)
- Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study. (2019) (62)
- Second-hand smoke as a predictor of smoking cessation among lung cancer survivors. (2014) (61)
- Induction treatment before surgery for non-small cell lung cancer. (2003) (60)
- Correlation of PD‐L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early‐Stage Squamous Cell Lung Carcinoma (2019) (60)
- Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trials. (2001) (59)
- Phase II study of accelerated hypofractionated three-dimensional conformal radiotherapy for stage T1-3 N0 M0 non-small cell lung cancer: NCIC CTG BR.25. (2014) (59)
- START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer. (2013) (59)
- Treatment of Small Cell Lung Cancer in the Elderly (1994) (59)
- Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma. (1997) (59)
- Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC). (2011) (59)
- Molecular heterogeneity of non‐small cell lung carcinoma patient‐derived xenografts closely reflect their primary tumors (2017) (59)
- Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. (2015) (58)
- Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. (2021) (58)
- A Randomized Phase 2 Study of Erlotinib Alone and in Combination with Bortezomib in Previously Treated Advanced Non-small Cell Lung Cancer (2009) (57)
- An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib. (2013) (57)
- Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). (2014) (56)
- Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer. (2015) (55)
- Loss of Phosphatase and Tensin Homolog Protein Expression Is an Independent Poor Prognostic Marker in Lung Adenocarcinoma (2012) (55)
- Relationship Between EGFR Expression, EGFR Mutation Status, and the Efficacy of Chemotherapy Plus Cetuximab in FLEX Study Patients with Advanced Non–Small-Cell Lung Cancer (2014) (54)
- Angiogenesis inhibitors in the treatment of lung cancer. (2001) (54)
- Evolution of Symptom Burden of Advanced Lung Cancer Over a Decade (2017) (53)
- A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10. (2004) (53)
- Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK). (2018) (53)
- Treatment of the Elderly When Cure is the Goal: The Influence of Age on Treatment Selection and Efficacy for Stage III Non-small Cell Lung Cancer (2011) (53)
- Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma. (1994) (53)
- Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk (2011) (53)
- Does Intensive Follow-up Alter Outcome in Patients with Advanced Lung Cancer? (2007) (53)
- Patients with Advanced Non–Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials? (2016) (52)
- A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 (2008) (52)
- Understanding prognostic gene expression signatures in lung cancer. (2009) (52)
- Time to adjuvant chemotherapy and survival in non–small cell lung cancer (2013) (52)
- Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes (2008) (51)
- Lung cancer screening with low-dose computed tomography: Canadian experience. (2007) (51)
- Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk (2018) (51)
- Venous thromboembolism and nonsmall cell lung cancer (2009) (50)
- Angiogenesis inhibitors under study for the treatment of lung cancer. (2003) (50)
- Derivation of Utility Values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire Values in Lung Cancer (2010) (49)
- Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24. (2010) (49)
- Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): Meta-analysis from four clinical trials. (2009) (48)
- L1 Cell Adhesion Molecule Promotes Tumorigenicity and Metastatic Potential in Non–Small Cell Lung Cancer (2012) (48)
- EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib (2017) (48)
- Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib and Erlotinib in the Treatment of Non-small Cell Lung Cancer: A Systematic Review (2006) (47)
- Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (2016) (47)
- A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts). (2013) (47)
- Validation of the short-form McGill pain questionnaire-2 in younger and older people with cancer pain. (2014) (47)
- An analysis of the prognostic and predictive importance of K-ras mutation status in the National Cancer Institute of Canada Clinical Trials Group BR.21 study of erlotinib versus placebo in the treatment of non-small cell lung cancer. (2006) (47)
- Validating the prognostic value of marker genes derived from a non-small cell lung cancer microarray study. (2004) (46)
- NRF2 Pathway Activation and Adjuvant Chemotherapy Benefit in Lung Squamous Cell Carcinoma (2015) (45)
- Utilization of prophylactic cranial irradiation in patients with limited stage small cell lung carcinoma (2010) (45)
- A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results. (2014) (45)
- Immunotherapy for Lung Cancer (2008) (45)
- [Immunotherapy for non-small cell lung cancer--novel approaches to improve patient outcome]. (2013) (45)
- Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: an overview (1995) (44)
- The communal coping model and cancer pain: the roles of catastrophizing and attachment style. (2012) (43)
- The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer. (2000) (43)
- Should aggressive surgery ever be part of the management of small cell lung cancer? (2004) (43)
- Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort. (2018) (42)
- Weighing Tumor Biology in Treatment Decisions for Patients with Non-small Cell Lung Cancer (2007) (42)
- Pharmacogenetic and Germline Prognostic Markers of Lung Cancer (2011) (41)
- Characterization of Lymphomas Developing in Immunodeficient Mice Implanted With Primary Human Non–Small Cell Lung Cancer (2012) (41)
- Hepatic arterial infusion of mitoxantrone in the treatment of primary hepatocellular carcinoma. (1987) (41)
- Referral Patterns for Adjuvant Chemotherapy in Patients with Completely Resected Non-small Cell Lung Cancer (2007) (41)
- Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy (2014) (41)
- Screening, diagnosis, and staging of lung cancer (1993) (40)
- Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers (2011) (40)
- Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. (2017) (40)
- Treatment of small‐cell lung cancer in elderly patients (2010) (40)
- Induction chemotherapy for locally advanced non-small cell lung cancer. (1993) (40)
- Enhancing treatment decision-making: pilot study of a treatment decision aid in stage IV non-small cell lung cancer (2008) (40)
- Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study (1999) (39)
- Clinical outcomes of extensive stage small cell lung carcinoma patients treated with consolidative thoracic radiotherapy. (2011) (39)
- Resource Utilization and Costs during the Initial Years of Lung Cancer Screening with Computed Tomography in Canada (2014) (39)
- Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer. (2017) (38)
- First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression. (2015) (38)
- Anti-IgA-mediated transfusion reactions in Canada. (1984) (38)
- Treatment of AIDS-related non-Hodgkin's lymphoma with a twelve week chemotherapy program. (1992) (38)
- First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status (2014) (38)
- Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial. (2009) (37)
- Acute lymphoblastic leukemia possible origin from a mediastinal germ cell tumor (1984) (37)
- Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer. (2013) (37)
- 3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies (2015) (37)
- Second line chemotherapy for NSCLC: establishing a gold standard. (2002) (37)
- Induction chemoradiotherapy facilitates radical resection of T4 non-small cell lung cancer invading the spine. (2009) (37)
- Targeting Angiogenesis in the Treatment of Lung Cancer (2008) (36)
- Complete clearance of plasma EGFR mutations as a predictor of outcome on osimertinib in the AURA trial. (2017) (36)
- A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer. (2006) (35)
- Improving Survival and Reducing Toxicity with Chemotherapy in Advanced Non-Small Cell Lung Cancer (2005) (35)
- Small cell lung cancer and targeted therapies (2007) (35)
- Low Prevalence of High-Grade Lesions Detected With Autofluorescence Bronchoscopy in the Setting of Lung Cancer Screening in the Pan-Canadian Lung Cancer Screening Study. (2015) (34)
- Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy (1995) (34)
- A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non–Small Cell Lung Cancer (2017) (34)
- Long-Term Outcome after En Bloc Resection of Non–Small-Cell Lung Cancer Invading the Pulmonary Sulcus and Spine (2013) (33)
- Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR‐Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study (2017) (33)
- TRIM14 is a Putative Tumor Suppressor and Regulator of Innate Immune Response in Non-Small Cell Lung Cancer (2017) (32)
- Phase I trial of radiation with concurrent and consolidation pemetrexed and cisplatin in patients with unresectable stage IIIA/B non-small-cell lung cancer. (2011) (32)
- Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non–Small Cell Lung Cancer Xenograft Models (2015) (32)
- Comparison of Tirazone (Tirapazamine) and cisplatin vs. etoposide and cisplatin in advanced non-small cell lung cancer (NSCLC): Final results of the international Phase III CATAPULT II Trial (2000) (32)
- Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: usefulness of mathematic modeling to determine maximum-tolerable dose. (1996) (32)
- Differential Role of Estrogen Receptor Beta in Early Versus Metastatic Non-small Cell Lung Cancer (2012) (31)
- Financial Burden Among Patients With Lung Cancer in a Publically Funded Health Care System. (2019) (31)
- Central Nervous System Pseudoprogression in a Patient Treated with PD-1 Checkpoint Inhibitor. (2015) (31)
- Efficacy Analysis for Molecular Subgroups in MARQUEE: a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial of Tivantinib (ARQ 197) Plus Erlotinib versus Placebo plus Erlotinib in Previously Treated Patients with Locally Advanced or Metastatic, Non-squamous, Non-small Cell Lung Cancer (NSCLC (2014) (31)
- Primary tumor xenografts of human lung adeno and squamous cell carcinoma express distinct proteomic signatures. (2011) (31)
- Treatment of recurrent small cell lung cancer. (2004) (30)
- Correlation of dosimetric and clinical factors with the development of esophagitis and radiation pneumonitis in patients with limited-stage small-cell lung carcinoma. (2015) (30)
- Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer (2006) (30)
- Immunotherapy for Non-small Cell Lung Cancer: Novel Approaches to Improve Patient Outcome (2011) (30)
- A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium. (2014) (29)
- Cetuximab plus platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC): a meta-analysis of randomized phase II/III trials (2009) (29)
- Epidermal growth factor receptor biomarkers in non-small-cell lung cancer: a riddle, wrapped in a mystery, inside an enigma. (2010) (28)
- Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514. (2009) (28)
- Intraocular Lymphoma: Report of Three Cases and Review of the Literature (1988) (28)
- A phase II multicenter trial comparing two schedules of lapatinib (LAP) as first or second line monotherapy in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) with either bronchioloalveolar carcinoma (BAC) or no smoking history (2007) (28)
- Adjuvant chemotherapy for completely resected non-small cell lung cancer: a systematic review. (2006) (28)
- Prognostic Gene Expression Signature for Squamous Cell Carcinoma of Lung (2010) (28)
- Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy. (2018) (28)
- Updated survival analysis of JBR.10: A randomized phase III trial of vinorelbine/cisplatin versus observation in completely resected stage IB and II non-small cell lung cancer (NSCLC). (2016) (28)
- Prognostic Value of Fibroblast Growth Factor Receptor 1 Gene Locus Amplification in Resected Lung Squamous Cell Carcinoma (2013) (28)
- Biomarker analysis from completely resected NSCLC patients enrolled in an adjuvant erlotinib clinical trial (RADIANT). (2009) (28)
- Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors. (2021) (28)
- Lymphoproliferative disorders after liver transplantation: imaging features (1998) (28)
- Detection of occult low-grade b-cell non-Hodgkin's lymphoma in patients with chronic hepatitis C infection and mixed cryoglobulinemia. (1999) (28)
- A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients. (2014) (27)
- A Pooled Exploratory Analysis of the Effect of Tumor Size and KRAS Mutations on Survival Benefit From Adjuvant Platinum-Based Chemotherapy in Node-Negative Non–Small Cell Lung Cancer (2012) (27)
- Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: the JBR.10 trial experience. (2007) (27)
- Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study. (2020) (26)
- Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS). (2013) (26)
- Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy (2015) (26)
- Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial (2014) (26)
- A phase II study of RAD001 (R) (everolimus) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I) (2007) (26)
- Adjuvant chemotherapy in elderly patients: An analysis of National Cancer Institute of Canada Clinical Trials Group and Intergroup BR.10. (2006) (26)
- Factors associated with referral to medical oncology and subsequent use of adjuvant chemotherapy for non-small-cell lung cancer: a population-based study. (2013) (25)
- Molecular analysis of the epidermal growth factor receptor (EGFR) gene and protein expression in patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial BR.21 (2005) (25)
- MA16.11 CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC: Pooled Data from Two Phase II Trials (2017) (25)
- PL-5 A phase III study of pemetrexed vs. docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) who were previously treated with chemotherapy (2003) (25)
- Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. (2019) (25)
- Gemcitabine in the treatment of non-small-cell lung cancer. (1995) (25)
- Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population (2018) (25)
- Postoperative chemotherapy in nonsmall cell lung cancer: a systematic review. (2006) (25)
- Pharmacogenetic Analysis of BR.21, a Placebo-Controlled Randomized Phase III Clinical Trial of Erlotinib in Advanced Non-small Cell Lung Cancer (2012) (25)
- Association of the 15q25 and 5p15 Lung Cancer Susceptibility Regions with Gene Expression in Lung Tumor Tissue (2012) (25)
- Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes (2011) (25)
- O-035 Phase III trial of concurrent chemotherapy and radiotherapy(CT/RT) vs CT/RT followed by surgical resection for stage IIIa(pN2)non-small cell lung cancer (NSCLC): Outcomes and implications for surgical management in North American Intergroup 0139 (RTOG 9309) (2005) (24)
- Combination chemotherapy and alpha-interferon in the treatment of Kaposi's sarcoma associated with acquired immune deficiency syndrome. (1988) (24)
- Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. (2018) (24)
- Early clearance of plasma EGFR mutations as a predictor of response to osimertinib in the AURA3 trial. (2018) (24)
- Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer. (2004) (24)
- Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage IIIA (T1-3, N2) unresectable non-small-cell lung cancer: final results of the Toronto phase II trial. (2005) (24)
- Treatment of advanced non-small cell lung cancer. (1994) (24)
- Malignant pericardial effusion. (1997) (24)
- Plasma pro-surfactant protein B and lung function decline in smokers (2015) (24)
- Gemcitabine/platinum alone or in combination with cetuximab as first-line treatment for advanced non-small cell lung cancer (NSCLC) (2007) (23)
- Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. (2015) (23)
- A drug discovery platform to identify compounds that inhibit EGFR triple mutants (2020) (23)
- Ongoing and future trials of biologic therapies in lung cancer. (2003) (23)
- Adjuvant Chemotherapy for Non-small Cell Lung Cancer: Practice Patterns and Outcomes in the General Population of Ontario, Canada (2012) (23)
- Adjuvant erlotinib (E) versus placebo (P) in non-small cell lung cancer (NSCLC) patients (pts) with tumors carrying EGFR-sensitizing mutations from the RADIANT trial. (2014) (23)
- IND.175: Phase I study of daily oral AZD2171, a vascular endothelial growth factor receptor inhibitor (VEGFRI), in combination with gemcitabine and cisplatin (G/C) in patients with advanced non-small cell lung cancer (ANSCLC): A study of the NCIC Clinical Trials Group (2007) (23)
- The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer. (2018) (23)
- Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI) (2019) (22)
- Primary bilateral adrenal lymphoma. (1997) (22)
- Importance of Long-term Low-Dose CT Follow-up after Negative Findings at Previous Lung Cancer Screening. (2018) (22)
- Randomized study of taxotere (TAX) versus best supportive care (BSC) in non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy (1999) (22)
- Tallimustine is inactive in patients with previously treated small cell lung cancer. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. (1996) (21)
- Smoking history is more predictive of survival benefit from erlotinib for patients with non-small cell lung cancer (NSCLC) than EGFR expression (2005) (21)
- Genetic interaction analysis among oncogenesis-related genes revealed novel genes and networks in lung cancer development (2019) (21)
- Phase I multicenter trial of BMS-690514: Safety, pharmacokinetic profile, biological effects, and early clinical evaluation in patients with advanced solid tumors and non-small cell lung cancer (2008) (21)
- The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statement (2009) (21)
- Dexamethasone/ifosfamide/cisplatin/etoposide (DICE) as therapy for patients with advanced refractory non-Hodgkin's lymphoma: preliminary report of a phase II study. (1991) (21)
- Real‐World EQ5D Health Utility Scores for Patients With Metastatic Lung Cancer by Molecular Alteration and Response to Therapy (2017) (21)
- Surgery for limited stage small cell lung cancer: time to fish or cut bait. (2010) (21)
- Chemotherapy for advanced non-small-cell lung cancer: modest progress, many choices. (2000) (20)
- Current paradigms in first-line treatment of non-small-cell lung cancer. (2004) (20)
- Elevated Platelet Count Appears to Be Causally Associated with Increased Risk of Lung Cancer: A Mendelian Randomization Analysis (2019) (20)
- Randomized trial of chemoradiotherapy to 61 Gy [no S] versus chemoradiotherapy to 45 Gy followed by surgery [S] using cisplatin etoposide in stage IIIa non-small cell lung cancer (NSCLC): intergroup trial 0139, RTOG (9309) (2003) (20)
- The Influence of Sex on Efficacy, Adverse Events, Quality of Life, and Delivery of Treatment in National Cancer Institute of Canada Clinical Trials Group Non-small Cell Lung Cancer Chemotherapy Trials (2010) (20)
- Depression and use of health care services in patients with advanced cancer. (2013) (20)
- Afatinib in patients with metastatic HER2-mutant lung cancers: An international multicenter study. (2017) (20)
- BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer. (2020) (19)
- Tarceva™ (erlotinib) exposure/effects (EE) analysis from a Phase III study in advanced NSCLC: Effect of smoking on the PK of erlotinib (2005) (19)
- Prognostic and predictive effects of KRAS mutation subtype in completely resected non-small cell lung cancer (NSCLC): A LACE-bio study. (2012) (19)
- Alternatives to chemotherapy and radiotherapy in the treatment of small cell lung cancer. (2001) (19)
- A 15-gene expression signature prognostic for survival and predictive for adjuvant chemotherapy benefit in JBR.10 patients (2008) (19)
- Two BRM promoter insertion polymorphisms increase the risk of early-stage upper aerodigestive tract cancers (2014) (19)
- A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196. (2017) (19)
- Alternatives to chemotherapy and radiotherapy as adjuvant treatment for lung cancer. (1997) (19)
- Nivolumab (N) plus ipilimumab (I) as first-line (1L) treatment for advanced (adv) NSCLC: 2-yr OS and long-term outcomes from CheckMate 012. (2017) (19)
- Phase I study of paclitaxel (Taxol) and ifosfamide in previously untreated patients with advanced non-small-cell lung cancer. A study of the National Cancer Institute of Canada Clinical Trials Group. (1996) (19)
- Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients (2016) (18)
- Induction treatment for resectable non-small-cell lung cancer. (1997) (18)
- NCIC CTG IND.190 Phase I Trial of Dalotuzumab (MK-0646) in Combination with Cisplatin and Etoposide in Extensive-Stage Small-Cell Lung Cancer (2014) (18)
- Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer. (2003) (18)
- Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. (2013) (18)
- Lung cancer in never smokers from the Princess Margaret Cancer Centre (2018) (17)
- Protein-altering germline mutations implicate novel genes related to lung cancer development (2020) (17)
- Polymorphisms of inflammatory and metalloproteinase genes, Helicobacter pylori infection and the risk of oesophageal adenocarcinoma (2008) (17)
- Venous thromboembolism in patients receiving multimodality therapy for thoracic malignancies. (2009) (17)
- Validation of treatment induced specific adverse effect as a predictor of treatment benefit: a case study of NCIC CTG BR21. (2008) (17)
- NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI. (2014) (17)
- A prospective randomized trial of Taxotere versus best supportive care (BSC) in patients with non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy: Survival update (2000) (17)
- Clinical use of blood, blood components and blood products. (1979) (17)
- HIV-associated lymphoma of the gastrointestinal tract: the University of Toronto AIDS-Lymphoma Study Group experience. (1995) (17)
- Anticoagulation and Bleeding: A Pooled Analysis of Lung Cancer Trials of the NCIC Clinical Trials Group (2009) (17)
- Exploiting the noise: improving biomarkers with ensembles of data analysis methodologies (2012) (16)
- PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non–Small-Cell Lung Cancer (2015) (16)
- LACE‐Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry‐based Biomarkers in Resected Non–small‐cell Lung Cancer (2019) (16)
- Surgical treatment of small cell lung cancer. (2003) (16)
- A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium (2009) (16)
- Locoregional failures following thoracic irradiation in patients with limited-stage small cell lung carcinoma. (2012) (16)
- Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. (2011) (16)
- Summary Statement Novel Agents in the Treatment of Lung Cancer: Fifth Cambridge Conference Assessing Opportunities for Combination Therapy (2008) (16)
- Clinical implementation of circulating tumour DNA testing for EGFR T790M for detection of treatment resistance in non-small cell lung cancer (2020) (15)
- Molecular selection of patients for first-line treatment of advanced non-small-cell lung cancer with epidermal growth factor inhibitors: not quite ready for prime time. (2008) (15)
- Angiogenesis inhibitors in the treatment of small cell and non-small cell lung cancer. (2004) (15)
- Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma (2018) (15)
- Maintenance Therapy in Advanced Non-small Cell Lung Cancer (2010) (15)
- Ifosfamide, cisplatin, and etoposide (ICE) in the treatment of advanced non-small cell lung cancer. (1992) (15)
- A phase I study of concurrent pemetrexed (P)/cisplatin (C)/radiation (RT) for unresectable stage IIIA/B non-small cell lung cancer (NSCLC) (2008) (15)
- A targeted approach to reducing lung cancer mortality. (2005) (14)
- ORAL01.03: CheckMate 012: Safety and Efficacy of First‐Line Nivolumab and Ipilimumab in Advanced NSCLC: Topic: Medical Oncology (2016) (14)
- A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer (2013) (14)
- Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. (2018) (14)
- Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer: the Canadian experience (1998) (14)
- The impact of anemia on outcome of chemoradiation for limited small-cell lung cancer: a combined analysis of studies of the National Cancer Institute of Canada Clinical Trials Group. (2007) (14)
- VP-16, ifosfamide and cisplatin (VIP) for extensive small cell lung cancer. (1994) (13)
- OA 17.03 First-Line Nivolumab plus Platinum-Based Doublet Chemotherapy for Advanced NSCLC: CheckMate 012 3-Year Update (2017) (13)
- Oral topotecan demonstrates clinical activity in relapsed non-small cell lung cancer. Results from an open-label, phase III study (387) comparing oral topotecan to intravenous docetaxel (2005) (13)
- Multi-institutional prospective validation of prognostic mRNA signatures in early stage squamous lung cancer (Alliance). (2020) (13)
- Molecular selection trumps clinical selection. (2011) (13)
- Integrating RAS Status into Prognostic Signatures for Adenocarcinomas of the Lung (2015) (12)
- A Rapid Outcomes Ascertainment System Improves the Quality of Prognostic and Pharmacogenetic Outcomes from Observational Studies (2008) (12)
- Age-Related Patterns in Cancer Pain and Its Psychosocial Impact: Investigating the Role of Variability in Physical and Mental Health Quality of Life (2018) (12)
- Resident preparedness in discussing prognosis in patients with advanced lung cancer (2010) (12)
- The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance. (2019) (12)
- Chemotherapy and surgery for operable NSCLC (2007) (12)
- Infection with the Human Immunodeficiency Virus: Clinical Manifestations and Their Relationship to Immune (1987) (12)
- Immunotherapy: a new standard of care in thoracic malignancies? (2018) (12)
- A genetic sequence variant (GSV) at susceptibility loci of 5p15.33 (TERT-CLPTM1L) is associated with survival outcome in locally advanced and metastatic non-small-cell lung cancer (NSCLC). (2014) (12)
- 1054PDNIVOLUMAB (ANTI-PD-1; BMS-936558, ONO-4538) IN COMBINATION WITH PLATINUM-BASED DOUBLET CHEMOTHERAPY (PT-DC) OR ERLOTINIB (ERL) IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC). (2014) (11)
- 3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses (2015) (11)
- Second-line chemotherapy for non-small cell lung cancer (2003) (11)
- Integrative analysis of non-small cell lung cancer patient-derived xenografts identifies distinct proteotypes associated with patient outcomes (2022) (11)
- Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model. (2016) (11)
- Randomized phase II study of maintenance vandetanib (ZD6474) in small cell lung cancer (SCLC) patients who have a complete or partial response to induction therapy: NCIC CTG BR.20 (2007) (11)
- Minimalist approaches to cancer tissue-of-origin classification by DNA methylation (2020) (11)
- Chemotherapy for relapsed small cell lung cancer: a clinical practice guideline (2006) (11)
- Erlotinib in the treatment of non-small cell lung cancer (2005) (11)
- Lung cancer in 2013: state of the art therapy for metastatic disease. (2013) (11)
- Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer. (2019) (11)
- Meta-analysis of the predictive and prognostic value of erlotinib-related biomarkers in phase III, placebo-controlled trials in non-small cell lung cancer (NSCLC): Recommendations of the BioLOGUE advisors. (2011) (10)
- A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196 (2017) (10)
- Outcomes of Long-term Interval Rescreening With Low-Dose Computed Tomography for Lung Cancer in Different Risk Cohorts. (2019) (10)
- Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials. (2001) (10)
- A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer (2019) (10)
- Real‐world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non‐small cell lung cancer (2019) (10)
- Phase I study of paclitaxel (TaxolQ) and ifosfamide in previously untreated patients with advanced non-small-cell lung cancer* (1996) (9)
- A Phase I Study of Pomalidomide (CC-4047) in Combination with Cisplatin and Etoposide in Patients with Extensive-Stage Small-Cell Lung Cancer (2013) (9)
- ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases. (2020) (9)
- Future directions in the treatment of non-small cell lung cancer. (1994) (9)
- LBA1 Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence (2020) (9)
- Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study. (2019) (9)
- Differential expression of matrix metalloproteinases and their inhibitors in nonâsmall cell lung cancer (2000) (9)
- Epidermal Growth Factor Receptor Inhibition in Lung Cancer (2013) (9)
- Randomized phase II-III study of matrix metalloproteinase inhibitor (MMPI) BMS-275291 in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC): NCIC-CTG BR.18. (2004) (9)
- Post study docetaxel in non-small cell lung cancer (NSCLC) patients after discontinuation from a randomized phase III trial of pemetrexed versus docetaxel: An exploratory analysis (2004) (9)
- Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. (2012) (9)
- Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial). (2013) (9)
- A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer. (2019) (9)
- Analytical Performance of a 15-Gene Prognostic Assay for Early-Stage Non-Small-Cell Lung Carcinoma Using RNA-Stabilized Tissue. (2015) (9)
- Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer. (2018) (9)
- Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC). (2021) (9)
- Confirmatory activity of gemcitabine in non small cell lung cancer (NSCLC) (1993) (9)
- [A phase II multicenter study of gemcitabine in non small cell lung cancers]. (1997) (9)
- Phase II study of elsamitrucin in non-small cell lung cancer (2004) (8)
- Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Non-Small Cell Lung Cancer. (2016) (8)
- BRM Promoter Polymorphisms and Survival of Advanced Non–Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial (2016) (8)
- A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancer. (2003) (8)
- Factors influencing a specific pathologic diagnosis of non-small-cell lung carcinoma. (2013) (8)
- Final results of the Canadian phase I dose escalation trial of gemcitabine and cisplatin for advanced non-small cell lung cancer. (1996) (8)
- A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer (2016) (8)
- ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients. (2016) (8)
- OA03.01 First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012 (2017) (8)
- Induction chemotherapy with MVP (mitomycin-C + vindesine + cisplatin) for stage III (T1-3, N2, M0) unresectable non-small cell lung cancer: the Toronto experience (1993) (8)
- Final results of a double-blind placebo-controlled study of adjuvant marimastat in small cell lung cancer (SCLC) patients responding to standard therapy (2001) (8)
- A randomised phase II study of gemcitabine/cisplatin alone and with herceptin in patients with HER2-positive non-small cell lung cancer (nsclc) (2001) (7)
- Dexamethasone (DEX) improves the efficacy of granisetron (GRAN) in the first 24 hours following high dose cisplatin (HDCP) chemotherapy (1993) (7)
- PD-064 Are age and co morbidity independent prognostic factors in thetreatment of metastatic non-small cell lung cancer (NSCLC): A review of a national cancer institute of Canada clinical trials group (NCIC-CTG) randomized trial (2005) (7)
- A phase II study of ifosfamide in combination with etoposide and cisplatin in the treatment of extensive small cell lung cancer. (1992) (7)
- O-268 Induction chemoradiotherapy and surgical resection for non-small cell lung carcinomas of the superior sulcus: Prediction and impact of pathologic complete response (CR) (2003) (7)
- Do Correlates of Pain-Related Stoicism and Cautiousness Differ in Younger and Older People With Advanced Cancer? (2017) (7)
- A guide to the investigation and treatment of patients with AIDS and AIDS-related disorders. (1986) (7)
- Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial. (2015) (7)
- The Impact of Brain Metastases and Associated Neurocognitive Aspects on Health Utility Scores in EGFR Mutated and ALK Rearranged NSCLC: A Real World Evidence Analysis. (2019) (7)
- Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: results from IALT, JBR.10 and ANITA. (2013) (7)
- OA 17.02 Updated Efficacy Results From the BIRCH Study: First-Line Atezolizumab Therapy in PD-L1–Selected Patients With Advanced NSCLC (2017) (7)
- Adjuvant chemotherapy after pulmonary resection for lung cancer. (2013) (6)
- An evaluation of the possible interaction of gastric acid suppressive medication and the EGFR tyrosine kinase inhibitor erlotinib. (2011) (6)
- Maintenance therapy comes of age for non-small-cell lung cancer, but at what cost? (2011) (6)
- Clinical Predictors of Early Mortality in Colorectal Cancer Patients Undergoing Chemotherapy: Results From a Global Prospective Cohort Study (2017) (6)
- Comparison of 3D Conformal Radiation Therapy (3DCRT) and Intensity Modulated Radiation Therapy (IMRT) in Stage III Non-small Cell Lung Cancer (NSCLC) (2012) (6)
- The role of chemotherapy in the treatment of small cell lung cancer. (1997) (6)
- 9009 A meta-analysis of four randomized phase II/III trials adding cetuximab to platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC) (2009) (6)
- Lung cancer driven by BRAFG469V mutation is targetable by EGFR kinase inhibitors. (2021) (6)
- Investigation of Leukocyte Telomere Length and Genetic Variants in Chromosome 5p15.33 as Prognostic Markers in Lung Cancer (2019) (6)
- Symptom response in non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib: Quality of life analysis of the NCIC CTG BR.21 trial (2005) (6)
- Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24. (2015) (6)
- NRF 2 Pathway Activation and Adjuvant Chemotherapy (2015) (6)
- Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress? (2008) (6)
- Post study docetaxel in non-small cell lung cancer (NSCLC) patients after discontinuation from a randomized phase III trial of pemetrexed versus docetaxel: An exploratory analysis. (2004) (6)
- Differentially expressed microRNAs in lung adenocarcinoma invert effects of copy number aberrations of prognostic genes (2018) (6)
- Cooperative group research efforts in lung cancer: focus on early-stage non-small-cell lung cancer. (2008) (6)
- Neurological Death is Common in Patients With EGFR Mutant Non-Small Cell Lung Cancer Diagnosed With Brain Metastases (2019) (6)
- Re: Gene expression-based prognostic signatures in lung cancer: ready for clinical use? (2010) (6)
- Evaluation of disease-free survival as surrogate endpoint for overall survival using two individual patient data meta-analyses of adjuvant chemotherapy in operable non-small cell lung cancer. (2011) (6)
- O-5 Multiple regression analysis of prognostic variables for survival from the phase III study of pemetrexed versus docetaxel in non-small-cell lung cancer (NSCLC) (2003) (6)
- Influence of gender on treatment outcome and toxicity in small cell lung cancer (SCLC). (2004) (6)
- Metabolites as Prognostic Markers for Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Platinum-Doublet Chemotherapy (2020) (6)
- Impact of clinical and molecular predictors of benefit from erlotinib in advanced non-small cell lung cancer on cost-effectiveness (2008) (6)
- Adjuvant Erlotinib (E) Versus Placebo (P) for Completely Resected Stage IB-IIIA EGFR-Positive (IHC/FISH) Non-Small Cell Lung Cancer (NSCLC): RADIANT Results (2014) (5)
- Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a clinical practice guideline (2006) (5)
- SHERLOC: A phase 2 study of MM-121 plus with docetaxel versus docetaxel alone in patients with heregulin (HRG) positive advanced non-small cell lung cancer (NSCLC). (2019) (5)
- Gastrointestinal Non-Hodgkin's Lymphoma. (1991) (5)
- P1.01-02 Long-Term Outcomes with First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up from CheckMate 012 (2018) (5)
- Pemetrexed in the treatment of non-small cell lung cancer. (2002) (5)
- C1-04: A phase II study of RAD001 (everolimus) monotherapy in patients with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I) (2007) (5)
- Preliminary cost-consequence analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as 2nd line therapy in advanced non-small cell lung cancer (2008) (5)
- Prognostic and predictive effects of TP53 mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). (2016) (5)
- Prognostic significance of nuclear excision (NER) and base excision (BER) DNA repair gene polymorphisms in esophageal cancer (2007) (5)
- 3113 AZD9291 in pre-treated patients with T790M positive advanced non-small cell lung cancer (NSCLC): Pooled analysis from two Phase II studies (2015) (5)
- Randomised phase II study of BMS-275291 versus placebo in patients (pts) with stage IIIb or IV non small cell lung cancer (NSCLC) receiving paclitaxel + carboplatin (PC): National Cancer Institute of Canada clinical trials group (NCIC CTG) br.18 (2001) (5)
- A phase II study of gemcitabine in the treatment of non small cell lung cancer (1997) (5)
- Non-small cell lung cancer (NSCLC) next generation sequencing (NGS) using the Oncomine Comprehensive Assay (OCA) v3: Integrating expanded genomic sequencing into the Canadian publicly funded health care model. (2019) (5)
- Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial (2022) (5)
- O-233 Platinum-based versus non-platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC): A meta-analysis of the published literature (2003) (5)
- The seventh tumor, node, metastasis staging system and lung cancer treatment choices: a matter of would, could, and should. (2010) (5)
- Quality of life (QOL) impact of adjuvant chemotherapy for early stage non-small cell lung cancer (NSCLC): Final analysis of JBR.10 randomized trial (2007) (5)
- Randomized phase 3 trial of amrubicin versus topotecan as second-line treatment for small cell lung cancer (SCLC) (2012) (5)
- Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system. (2022) (4)
- Systemic Inflammatory Markers of Survival in Epidermal Growth Factor-Mutated Non-Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis. (2021) (4)
- Serum proteomic classifier for predicting response to epidermal growth factor receptor inhibitor therapy: have we built a better mousetrap? (2007) (4)
- Ifosfamide and paclitaxel combinations for the treatment of advanced non-small cell lung cancer. (1998) (4)
- A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma. (2005) (4)
- Adoption of adjuvant chemotherapy (ACT) for non-small cell lung cancer (NSCLC) in the elderly: A population-based outcomes study. (2011) (4)
- A Randomized Phase II study of Reolysin in Patients with Previously Treated Advanced or Metatstatic Non Small Cell Lung Cancer (NSCLC) receiving Standard Salvage Chemotherapy – Canadian Cancer Trials Group IND 211. (2016) (4)
- Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer (2022) (4)
- Intrathoracic complications of malignancy and its treatment (1995) (4)
- Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients (2021) (4)
- Referral patterns for adjuvant therapy in non-small cell lung cancer (2005) (4)
- Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis. (2018) (4)
- CEA: A Useful Prognostic Marker in Small Cell Lung Cancer (1985) (4)
- Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy. (2021) (4)
- 14 A randomized study of CODE plus thoracic irradiation versus alternating CAVEP for extensive stage small cell lung cancer (ESCLC): An intergroup study of the national cancer institute of Canada and the southwest oncology group (1997) (4)
- O-201 A phase II trial of induction chemotherapy followed by extrapleural pneumonectomy and high-dose hemithoracic radiation for malignant pleural mesothelioma (2003) (4)
- Phase II study of sulofenur (LY 186641) in untreated patients with extensive small cell lung cancer (1991) (4)
- Identifying patients with non-small cell lung cancer (NSCLC) unlikely to benefit from erlotinib: An exploratory analysis of National Cancer of Institute of Canada Clinical Trials Group BR.21. (2006) (4)
- Common and rare EGFR mutations (EGFRm) in the RADIANT trial: Final follow-up with 5 year data. (2015) (4)
- A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC). (2016) (4)
- Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancer. (2022) (4)
- The effect of two BRM promoter variants on the risk of stage I/II upper aerodigestive tract cancers. (2012) (4)
- The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer (2022) (4)
- The impact of body mass index on survival in stage 3 and 4 lung cancer. (2013) (4)
- A Cost‐Effectiveness Analysis of Using the JBR.10‐Based 15‐Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non–Small‐Cell Lung Cancer (2017) (4)
- Single agent Gemcitabine for elderly patients with non small cell lung cancer (NSCLC): A phase II study (2000) (4)
- Correlation of immune-related adverse events and response from immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (2020) (4)
- Influence of gender on treatment outcome and toxicity in small cell lung cancer (SCLC) (2004) (4)
- Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib. (2020) (4)
- Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? Yes, there is a role for EGFR TKIs in these patients. (2016) (4)
- New Drugs in Lung Cancer (1999) (3)
- An Anaplastic Lymphoma Kinase Immunohistochemistry–Negative but Fluorescence In Situ Hybridization–Positive Lung Adenocarcinoma Is Resistant to Crizotinib (2016) (3)
- Treatment of primary hepatocellular carcinoma by hepatic arterial infusion of 4'-epirubicin (1990) (3)
- Phase I/II study of GTI-2040 plus docetaxel as 2nd-line treatment in non-small cell lung cancer (NSCLC) and other solid tumors (2005) (3)
- P89.03 Demonstrating VALUE of Liquid Biopsy for Lung Cancer in a Public Healthcare System (2021) (3)
- P3-068: An economic analysis of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) BR.21, a randomized trial of erlotinib versus best supportive care after cisplatin based chemotherapy in advanced non-small-cell lung cancer (NSCLC) (2007) (3)
- A Career in Lung Cancer: Pushing Beyond Chemotherapy. (2019) (3)
- Single agent gemcitabine activity in non-small cell lung cancer (1997) (3)
- Exploratory subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase III study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC). (2016) (3)
- 6516 ORAL Venous thromboembolism (VTE) and non-small cell lung cancer (NSCLC): a pooled analysis of National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trials (2007) (3)
- MA 03.06 Effect of 2L Ramucirumab after Rapid Time to Progression on 1L Therapy: Subgroup Analysis of REVEL in Advanced NSCLC (2017) (3)
- Pemetrexed is more effective in patients with nonsquamous non-small cell lung cancer (NSCLC) histology: an analysis of three large, randomized, phase III trials (2009) (3)
- Immunohistochemical validation study of 15-gene biomarker panel predictive of benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of JBR.10 (2020) (3)
- Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsy (2022) (3)
- Demonstrating the value of liquid biopsy for lung cancer in a public health care system. (2020) (3)
- Upfront next generation sequencing in NSCLC: A publicly funded perspective. (2018) (3)
- EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft models. (2020) (3)
- EVALUATION OF PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL WHEN EVALUATING THE EFFECT OF CHEMOTHERAPY AND RADIOTHERAPY IN LOCALLY ADVANCED LUNG CANCER USING DATA FROM FOUR INDIVIDUAL PATIENT DATA META-ANALYSES (2011) (3)
- PL03.03: Randomized Phase III Study of Osimertinib vs Platinum-Pemetrexed for EGFR T790M-Positive Advanced NSCLC (AURA3) (2017) (3)
- Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial (2023) (3)
- Lung cancer in never-smokers from the Princess Margaret Cancer Centre. (2014) (3)
- Factors influencing a specific histologic diagnosis of non-small cell lung cancer. (2011) (3)
- A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG plus ), locally advanced or metastatic non-small cell lung cancer (NSCLC) (2016) (3)
- Prospective assessment of cardiac function in patients with Kaposi's sarcoma and the acquired immune deficiency syndrome. (1991) (3)
- Prognostic effect of single versus multiple somatic mutations in non-small cell lung cancer (NSCLC). (2015) (3)
- CNS outcomes in EGFR/ALK wild-type NSCLC patients with brain metastases treated with immune checkpoint inhibitors (ICI). (2020) (3)
- The influence of sex on efficacy, toxicity and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) non-small cell lung cancer (NSCLC) chemotherapy trials (2008) (3)
- Associationof the 15 q 25 and 5 p 15 LungCancerSusceptibility Regions with Gene Expression in Lung Tumor Tissue (2012) (3)
- Phase I trial of gemcitabine and cisplatin in advanced non-small cell lung cancer: a preliminary report. (1996) (3)
- Exploratory analysis of angiotensin converting enzyme (ACE) and aldosterone (Ald) serum levels as prognostic and predictive biomarkers on the NCIC CTG BR24 trial. (2013) (3)
- Are age and comorbidity independent prognostic factors in the treatment of metastatic NSCLC? A review of prospectively randomized national cancer institute of Canada Clinical Trials Group (NCIC CTG) trials. (2006) (3)
- Helicase-like transcription factor expression is associated with a poor prognosis in Non-Small-Cell Lung Cancer (NSCLC) (2018) (3)
- The impact of symptoms and comorbidity on health utility scores and health-related quality of life in small cell lung cancer using real world data (2020) (3)
- Prognostic and Predictive Values of KRAS in EGFR-Based Subgroups and Combined With p53 in Completely Resected Non-Small Cell Lung Cancer (NSCLC): A Lace-Bio Study (2012) (3)
- Somatic Alteration Burden Involving Non-Cancer Genes Predicts Prognosis in Early-Stage Non-Small Cell Lung Cancer (2019) (3)
- A phase II study of ifosfamide, cisplatin, etoposide in patients with advanced non-small cell lung cancer: a preliminary report. (1990) (3)
- P53 protein over-expression but not p53 gene mutation is a poor prognostic marker and a predictive marker for survival benefit from adjuvant chemotherapy in non-small cell lung cancer (NSCLC) in the JBR.10 Trial (2007) (3)
- OA06.03 Patient-Reported Outcomes from ADAURA: Osimertinib as Adjuvant Therapy in Patients with Resected EGFR Mutated (EGFRm) NSCLC (2021) (3)
- Vinorelbine (Navelbine) in the adjuvant and neoadjuvant treatment of non-small cell lung cancer. (1994) (3)
- Longitudinal health utilities, symptoms and toxicities in patients with ALK-rearranged lung cancer treated with tyrosine kinase inhibitors: a prospective real-world assessment. (2020) (3)
- The impact of brain metastases on overall survival (OS) in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) clinical trials (CT) in advanced non-small cell lung cancer (NSCLC). (2009) (3)
- Randomized phase III trial of gemcitabine/carboplatin with or without iniparib (BSI-201) in patients with previously untreated stage IV squamous non-small cell lung cancer (NSCLC). (2011) (3)
- Sequencing of systemic therapies in advanced NSCLC with MET exon 14 skipping mutation: A multicenter experience. (2021) (3)
- A randomized trial of the electronic Lung Cancer Symptom Scale for quality-of-life assessment in patients with advanced non-small-cell lung cancer. (2019) (2)
- 1174OPROGNOSTIC AND PREDICTIVE ROLES OF EGFR COPY NUMBER AND KRAS MUTATION STATUS FROM THE RADIANT TRIAL OF ADJUVANT ERLOTINIB (E) VERSUS PLACEBO (P). (2014) (2)
- EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC. (2021) (2)
- Acute Leukemia during Pregnancy: The Toronto Leukemia Study Group Experience with Long-term Follow-up of Children Exposed in Utero to Chemotherapeutic Agents (1988) (2)
- The impact of tobacco retail density on overall survival (OS) in lung cancer survivors. (2020) (2)
- Global prospective cohort study of factors associated with early mortality in patients with lung cancer undergoing chemotherapy. (2016) (2)
- Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer. (1996) (2)
- Predictive versus prognostic value of lung adenocarcinoma classification. (2015) (2)
- P3.04-20 Correlation of Immune-Related Adverse Events and Response from Immune Checkpoint Inhibitors in Patients with Advanced NSCLC (2018) (2)
- Automating Access to Real-World Evidence (2022) (2)
- State of the Art Treatment for Lung Cancer (2013) (2)
- A drug interaction study between dextromethorphan and panobinostat (LBH589), an orally active deacetylase inhibitor, in patients with advanced cancer. (2010) (2)
- Phase II study of sulofenur (LY186641) in untreated patients with extensive small cell lung cancer. (1991) (2)
- Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial (2023) (2)
- Effect of BRM promoter variants on survival outcomes of stage III-IV non-small cell lung cancer (NSCLC) patients. (2013) (2)
- 233 The influence of age on the efficacy and tolerability of combined modality therapy in limited small cell lung cancer (L-SCLC) (1997) (2)
- Compliance with oral topotecan in patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). (2006) (2)
- Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials (2022) (2)
- Psychometric Evaluation of the Pain Attitudes Questionnaire-Revised for People With Advanced Cancer. (2017) (2)
- Predictors of Venous Thmromboembolism in Colorectal Cancer: Results from a Global Prospective Study (2016) (2)
- An economic analysis of National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) JBR.10, a randomized trial of adjuvant vinorelbine plus cisplatin versus observation in early stage non-small cell lung cancer (NSCLC). (2006) (2)
- Predictors of early mortality in colorectal cancer patients undergoing chemotherapy: Results from a global prospective cohort study. (2014) (2)
- Impact of KRAS mutational variant on response to immunotherapy in metastatic NSCLC. (2021) (2)
- Retrospective study of the incidence and outcomes from lung cancer in solid organ transplant recipients. (2020) (2)
- Final follow-up (f/u) results from RADIANT: A randomized double blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection in patients (pts) with stage IB–IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC). (2015) (2)
- Complementary medicine (CM) use in phase III clinical trials (P3T) conducted by the Canadian Cancer Trials Group (CCTG) (2019) (2)
- PD-101 Review of practice patterns for adjuvant chemotherapy inpatients with completely resected non-small cell lung cancer (NSCLC) (2005) (2)
- Predictors of clinically significant bleeding in colorectal cancer: Results from a global prospective cohort study. (2014) (2)
- Analysis of treatment duration and safety of adjuvant erlotinib (E) versus placebo (P) after surgery in patients (pts) with non-small cell lung cancer (NSCLC): RADIANT trial. (2014) (2)
- Second-line chemotherapy for non-small cell lung cancer: is more better or just simply more? (2002) (2)
- TCR clonality and Treg frequency as predictors of outcome in stage III NSCLC treated with durvalumab. (2020) (2)
- Correlation of primary tumor engraftment in immune deficient mice and relapse rate in patients with early-stage non-small cell lung carcinoma (NSCLC). (2009) (2)
- Class III beta tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: Analysis of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) study JBR.10. (2006) (2)
- Patient-reported outcomes (PROs) with first-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic NSCLC: Results from MYSTIC. (2019) (2)
- Outcomes of EGFR-mutant lung adenocarcinomas (AC) that transform to small cell lung cancer (SCLC). (2018) (2)
- Elimination of second-hand smoke (SHS) exposure after a lung or head and neck (HN) cancer diagnosis and subsequent patient smoking cessation. (2016) (2)
- A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer. (2021) (2)
- Predictive value of coexisting KRAS and TP53 mutations on response to chemotherapy in non-small cell lung cancer (NSCLC). (2015) (2)
- Single cell analysis reveals transcriptomic features of drug tolerant persisters and stromal adaptation in a patient-derived EGFR-mutated lung adenocarcinoma xenograft model. (2022) (1)
- Point-Of-Care Spirometry Identifies High-Risk Individuals Excluded from Lung Cancer Screening. (2020) (1)
- MA08.02 Outcomes of Early Stage ALK-positive NSCLC patients in a Real-World Cohort (2021) (1)
- Evaluation of stored liquid biopsies for molecular profiling in patients with non-small cell lung cancer (NSCLC). (2017) (1)
- CHEMOTHERAPY (CT) PLUS CETUXIMAB AS 1ST-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): META-ANALYSIS OF INDIVIDUAL PATIENT DATA (2010) (1)
- P2.03-03 Upfront Next Generation Sequencing in NSCLC: A Publicly Funded Perspective (2018) (1)
- P-270 Lung cancer screening using low-dose computed tomography:The Toronto experience (2005) (1)
- MA18.09 Predictors of Health Utility Scores (HUS) in Advanced EGFR-Mutated NSCLC (2018) (1)
- P2.04-013 ElevatION:NSCLC-101 – A Phase 1b Study of PDR001 Combined with Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients (2017) (1)
- Human Cancer Biology L 1 Cell Adhesion Molecule Promotes Tumorigenicity and Metastatic Potential in Non – Small Cell Lung Cancer (2012) (1)
- 1195P The value of detecting resistance through liquid biopsy (2020) (1)
- NCIC IND.190: A phase I trial of MK-0646 in combination with cisplatin and etoposide in extensive-stage small cell lung cancer (ES SCLC). (2012) (1)
- Comparing health utility scores, treatments, and outcomes in lung cancer patients with rare EGFR mutations with those with exon 19 deletion (del) and L858R mutations. (2019) (1)
- 1177PDEGFR DEL19/L858R ACTIVATING MUTATION (M+) SUBGROUP IN RADIANT: BASELINE CHARACTERISTICS, PROGNOSTIC ROLE, AND DISEASE-FREE SURVIVAL (DFS) BY STAGE. (2014) (1)
- P1.13-11 PRO-CTCAE Toxicities in Advanced NSCLC Patients with EGFR Mutations: A Real World Assessment (2018) (1)
- Pooled analysis of venous thromboembolism (VTE) from four trials of necitumumab and chemotherapy for stage IV non-small cell lung cancer (NSCLC). (2016) (1)
- 50 – Immunotherapy and Lung Cancer (2018) (1)
- Cell Adhesion Molecule Promotes Tumorigenicity and Metastatic Potential in Non – Small Cell Lung Cancer (2012) (1)
- Abstract 1184: Modeling mechanisms of resistance of epidermal growth factor receptor (EGFR) mutations to targeted drugs through patient-derived xenografts (PDX) of non-small cell lung cancer (NSCLC) (2014) (1)
- Dose scheduling & drug tolerability in phase II studies of gemcitabine and cisplstin chemotherapy for non-small cell lung cancer (1997) (1)
- Bone metastases as predictors of treatment response and rapidly progressive disease in NSCLC patients on PD-1/PD-L1 immune checkpoint inhibitors (ICI). (2019) (1)
- Longitudinal Health Utilities, Symptoms and Toxicities in Patients with ALK-Rearranged Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Prospective Real-World Assessment. (2020) (1)
- Phase II trial of MTA (AlimtaTM) and cisplatin in patients with advanced Non-Small Cell Lung Cancer (NSCLC) (2000) (1)
- O-118 The significance of K-ras mutations in the Intergroup JBR.10 Trial on adjuvant chemotherapy in completely resected early stage non-small cell lung cancer (NSCLC) patients (2005) (1)
- The role of gemcitabine in the treatment of small cell lung cancer (1997) (1)
- Association of Two Brm Promoter Variants with Survival Outcomes of Stage IV Non Small Cell Lung Cancer (NSCLC) Patients (2012) (1)
- Patients with advanced non-small cell lung cancer (NSCLC): Are research biopsies a barrier to participation in clinical trials? (2015) (1)
- 237 What is standard therapy for stage IIIA non-small cell lung cancer (NSCLC)?: A randomized trial of combination chemotherapy (C) and surgery (S) versus radiotherapy (RT) alone (1997) (1)
- P2.01-055 Examining Metabolomics as a Prognostic Marker in Metastatic Non–Small Cell Lung Cancer Patients Undergoing First-Line Chemotherapy (2017) (1)
- Docetaxel versus supportive care in previously treated patients with non-small cell lung cancer (NSCLC): Analysis of quality of life and clinical benefit parameters in a randomized trial (2000) (1)
- A phase I study of BMS-936558 in combination with gemcitabine/cisplatin, pemetrexed/cisplatin, or carboplatin/paclitaxel in patients with treatment-naive, stage IIIB/IV non-small-cell lung cancer. (2012) (1)
- Exploiting the noise: improving biomarkers with ensembles of data analysis methodologies (2012) (1)
- Venous Thromboembolism and Non-Small Cell Lung Cancer: A Pooled Analysis of National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trials. (2007) (1)
- Diffuse Hemorrhagic Brain Metastases in an ALK Fusion Positive Patient on Crizotinib. (2015) (1)
- The effect of prior cancer on non‐small cell lung cancer trial eligibility (2021) (1)
- Targeted therapy in the management of lung cancer: is there more hype than hope? (2008) (1)
- Change in second-hand smoke exposure after a lung and head and neck cancer diagnosis and subsequent patient smoking cessation. (2015) (1)
- MA18.07 Identification of Neuroendocrine Transformation in Anaplastic Lymphoma Kinase Rearranged (ALK+) Tumors After Tyrosine Kinase Inhibitors (2019) (1)
- MTE01.02 Lung Patient Derived Xenograft and Organoid (2018) (1)
- Effects of Ethnicity on Outcomes of Patients With EGFR Mutation–Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection (2021) (1)
- OA16.02 The Economic Value of Liquid Biopsy for Genomic Profiling in Advanced Non-Small Cell Lung Cancer (2021) (1)
- 167OPROGNOSTIC AND PREDICTIVE BIOMARKERS FOR ACT (ADJUVANT CHEMOTHERAPY) IN RESECTED NON-SMALL CELL LUNG CANCER (R-NSCLC): LACE-BIO. (2014) (1)
- P3.03-29 The Prognostic Effect of Tumor Mutation Burden and Smoking History in Resected EGFR Mutant Non-Small Cell Lung Cancer (2018) (1)
- P-331 For richer, for poorer: A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer (2005) (1)
- O-126 Expression profiling of matrix metalloproteinases (MMPs) and inhibitors reveals a novel prognostic role for MMP-19 in patients with non-small cell lung cancer (2005) (1)
- Concurrent Pemetrexed/Cisplatin/Radiation for Unresectable Stage IIIA/B Non-Small Cell Lung Cancer: A Phase I/II Study (2007) (1)
- 1217P Breathomics eNose technology as a non-invasive, inexpensive, point-of-care predictive test to detect early stage lung cancer in never or former light smokers (2020) (1)
- Advances in Brief Molecular Profiling of Non-Small Cell Lung Cancer and Correlation with Disease-free Survival 1 (2002) (1)
- Cabazitaxel (Cbz) versus topotecan in patients (pts) with small cell lung cancer (SCLC) that has progressed during or after first-line treatment with platinum-based chemotherapy: A randomized phase II study. (2013) (1)
- Optimizing Drug Response Study Design in Patient-Derived Tumor Xenografts (2022) (1)
- A Q-TWiST analysis of adjuvant chemotherapy in non-small cell lung cancer (NSCLC) in the NCIC CTG JBR.10 trial (2008) (1)
- P-253 Anemia as a prognostic factor in induction chemotherapy for stage IIIA N2 non small cell lung cancer (NSCLC) (2003) (1)
- Surgery for early non-small cell lung cancer with preoperative erlotinib (SELECT): A correlative biomarker study. (2013) (1)
- Willingness of patients to provide biologic samples for pharmacogenomic testing. (2013) (1)
- Treatment Patterns and Outcomes of Patients With Advanced Pleural Mesothelioma at an Academic Referral Centre. (2021) (1)
- Erratum: Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer: An analysis of National Cancer institute of Canada and intergroup trial JBR.10 and a review of the literature (Lung Cancer (2005) 47 (385-394) DOI: 10.1016/j.lungcan.2004.08.016. (2005) (1)
- Individualized therapy in the adjuvant setting for non-small cell lung cancer (NSCLC) (2013) (1)
- The interaction between smoking status and disease stage on non-small cell lung cancer (NSCLC) survival. (2010) (1)
- P35.03 Methylation Signatures Associated with T790M Status in Progressive NSCLC (2021) (1)
- Reply to T. Valerius (2010) (1)
- Angiogenic factors and soluble receptors in NCIC CTG BR.24. (2011) (1)
- Long-term outcome after resection of non-small cell lung cancer invading the thoracic inlet. (2014) (1)
- Effect of brain metastases on survival and systemic treatment of EGFR/ALK-driven non-small cell lung cancer (NSCLC). (2016) (1)
- Identi fi cation of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk (2018) (1)
- A Phase III Comparison of Prophylactic Cranial Irradiation versus Observation in Patients with Locally Advanced Non-Small Cell Lung Cancer (RTOG 0214): How to Improve Accrual to an Important Prospective Randomized Study (2005) (1)
- Outcomes of Bimodality and Trimodality Therapy in Patients with Stage III Non-small Cell Lung Cancer (NSCLC) (2010) (1)
- Financial toxicity among patients with lung cancer in a publicly funded health care system. (2018) (1)
- Abstract 4912: Systematic, comparative network analysis on non-small cell lung cancer (2012) (1)
- Mitochondrial Aconitase ACO2 Links Iron Homeostasis with Tumorigenicity in Non–Small Cell Lung Cancer (2022) (1)
- 92 POSTER Effects of AZD2171 on pharmacokinetics (PK) of carboplatin (C) and paclitaxel (P) in patients with advanced non-small cell lung cancer (NSCLC): a study of the National Cancer Institute of Canada Clinical Trials Group (2006) (1)
- P1-139: A survey of Canadian practice in management of malignant pleural mesothelioma (MPM) (2007) (1)
- Preliminary results of BEAVER: An investigator-initiated phase II study of binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts). (2021) (1)
- 71. MGMT PROMOTER METHYLATION IS A PROGNOSTIC BIOMARKER IN EGFR MUTANT LUNG ADENOCARCINOMA WITH BRAIN METASTASES (2020) (1)
- EGFR and ABCG2 polymorphisms as prognostic and predictive markers in the NCIC CTG BR.21 trial of single-agent erlotinib in advanced non-small cell lung cancer (NSCLC). (2010) (1)
- SMALL CELL LUNG CANCER (2008) (1)
- Tobacco retail availability and tobacco cessation in lung and head and neck (HN) cancer survivors. (2019) (1)
- Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer. (2022) (1)
- Quantifying EpCAM heterogeneity of circulating-tumor-cells (CTCs) from small cell lung cancer (SCLC) patients. (2019) (1)
- Targeted therapy for lung cancer (2005) (0)
- P1.03-041 Do Several Rounds of Negative Screening Low Dose CT Scans Influence the Risk to Develop Lung Cancer?: Topic: Screening (2017) (0)
- 1178PDCOMMON AND RARE EGFR MUTATIONS (EGFRM) IN THE RADIANT TRIAL. (2014) (0)
- P2.13-45 SHERLOC: A Phase 2 Study of Seribantumab in Combination with Docetaxel in Patients with Heregulin Positive, Advanced NSCLC (2018) (0)
- P3.02b-028 Characterizing Residual Erlotinib-Tolerant Population Using EGFR-Mutated NSCLC Primary Derived Xenografts: The Last Holdouts: Topic: EGFR Biomarkers (2017) (0)
- Using Recurrent Neural Networks to Extract High-Quality Information From Lung Cancer Screening Computerized Tomography Reports for Inter-Radiologist Audit and Feedback Quality Improvement. (2023) (0)
- Clinical, pathological and genetic predictors of patient-derived xenograft (PDX) engraftment in EGFR-mutated lung adenocarcinoma (LUAD). (2019) (0)
- Treatment with PD-1 inhibitors in NSCLC beyond disease progression: Impact on symptoms and cost. (2018) (0)
- Safety of full dose anticoagulation in autologous stem cell transplantation (1997) (0)
- Barriers and facilitators to implementation of serial point-of-care hearing tests using a novel iPad-based audiometry in platinum chemotherapy-treated cancer patients (pts). (2020) (0)
- P-930 Results of induction chemoradiation followed by surgery forStage 3A-N2 non-small cell lung cancer (2005) (0)
- P2.03b-008 The Impact of Brain Metastases and Their Treatment on Health Utility Scores in Molecular Subsets of Lung Cancer Patients: Topic: Brain Meta (2017) (0)
- A Phase I/Ib study of MEK162 (binimetinib), a MEK inhibitor, in combination with carboplatin and pemetrexed in patients with non-squamous NSCLC. (2016) (0)
- Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non-small Cell Lung Cancer (2010) (0)
- P2.03-37 Genomic Landscape of EGFR/ALK Wild-Type Lung Adenocarcinomas in Never-Smokers and Importance of Epithelial-Mesenchymal-Transition (2019) (0)
- Pulmonary Kaposi's Sarcoma: Diagnostic Features and Natural History in Patients with Acquired Immuneodeficiency Syndrome (1996) (0)
- Non-driver somatic alteration burden confers good prognosis in non-small cell lung cancer (2018) (0)
- Lung Cancer Driven by BRAF Mutation Is Targetable by EGFR Kinase Inhibitors (2022) (0)
- The influence of patient-reported adverse events on Health Utility Score (HUS) and Health-Related Quality of Life (HRQoL) in small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) patients. (2018) (0)
- 81P The influence of comorbidity on health utility score (HUS) and health-related quality of life (HRQoL) in small cell lung cancer (SCLC) compared to non-small cell lung cancer (NSCLC) (2018) (0)
- Global Prospective Cohort Study of Factors Associated with Venous Thromboembolism in Patients with Lung Cancer Receiving Cancer Therapy (2016) (0)
- Effect of molecular profile in non-small cell lung carcinoma on the development of brain metastases. (2016) (0)
- Chemotherapy for Small Cell Lung Cancer 58 (2018) (0)
- Unresectable non-small cell lung cancer (NSCLC) as a target for clinical trials of AG3340, a selective inhibitor of matrix metalloproteases (MMPs), in combination with standard chemotherapies (1999) (0)
- DPD defi ciency in patients treated with fl uorouracil (2015) (0)
- P2.01-46 Investigating the Effects of Prior Malignancy on NSCLC Trial Eligibility (2018) (0)
- (311) Acceptance of pain: A preliminary study in advanced cancer patients (2008) (0)
- Reply to “On Plain Language and Going Astray” (2011) (0)
- Protein-altering germline mutations implicate novel genes related to lung cancer development (2020) (0)
- The effect of prior smoking history on the molecular profile of EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC). (2018) (0)
- Abstract 1869: Methylation signatures associated with T790M status in progressive NSCLC (2020) (0)
- P2.03b-071 Therapeutic Targeting of the Phosphatidylinositol-3 Kinase Pathway in Lung Squamous Cell Carcinoma: Topic: Biomarkers (2017) (0)
- P14.09 Early Expansion of M-MDSCs and High Plasma TSLP levels as Predictors of Primary Resistance to PD1 Inhibitors in Metastatic NSCLC (2021) (0)
- Personalized treatment outcomes in never smokers with advanced non-small cell lung cancer (NSCLC) in the Princess Margaret Cancer Centre. (2015) (0)
- MA17.06 Landscape of Somatic Mutations Involving Lung Cancer Associated Genes in Non-Small Cell Lung Cancer (NSCLC) Patient-Derived Xenografts (2017) (0)
- MA18.07 Awareness of the Harms of Continued Smoking Among Lung Cancer (LC) Survivors (2018) (0)
- 97 Yet another test?! Does repeat imaging help in the management of lung cancer? (2006) (0)
- Robert J. Ginsberg, MD FRCS(C), March 30, 1940–March 1, 2003 (2003) (0)
- Factors associated with referral to medical oncology (MO) and subsequent use of adjuvant chemotherapy (ACT) among patients with resected non-small cell lung cancer (NSCLC): A population-based study. (2012) (0)
- OA13.01 SPECS2 Lung Cancer Consortium Prospective Multicenter Validation of Prognostic Signature for Early Stage Squamous Lung Cancer (2019) (0)
- 1165P Modelling long-term survival outcomes in patients with stage (stg) IB–IIIA EGFR-mutated NSCLC from the ADAURA trial (2021) (0)
- Kaposi's sarcoma and AIDS: a variable spectrum. (1989) (0)
- Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy (2021) (0)
- P-658 Expression and prognostic significance of c-Kit, PKB/Akt and MAPK in patients with small-cell lung cancer (2003) (0)
- Paclitaxel and ifosfamide combinations for non-small cell lung cancer (1997) (0)
- Patterns of Failure in Patients with Limited-Stage Small Cell Lung Carcinoma (2010) (0)
- Impact of hemoglobin (Hb) on outcomes of adjuvant chemotherapy (ACT) with cisplatin/vinorelbine in patients (pts) with completely resected non-small cell lung cancer (NSCLC) in JBR.10 (2005) (0)
- PD3-2-5: Preoperative gefitinib in clinical stage I NSCLC (2007) (0)
- MA27.01 Establishment of PDX From Tumors Characterized by EGFR Mutations or ALK Fusion Genes from Resections, Biopsies and Pleural Fluids (2018) (0)
- Pemetrexed in the treatment of non[ndash ]small cell lung cancer (2002) (0)
- Abstracts from the Fourteenth Rambam Research Day, December 7, 2017 (2018) (0)
- P1.05-006 Identification of miRNAs and mRNAs Associated with Metastasis in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Topic: Translational Research and Biomarkers (2017) (0)
- PD-L1 assessment in cytology samples predicts treatment response to checkpoint inhibitors in NSCLC. (2022) (0)
- PCN10 COSTS OF MANAGING TOXICITIES IN ADVANCED NON-SMALL CELL LUNG CANCER WITH PEMETREXED COMPARED WITH DOCETAXEL AS SECOND-LINE CHEMOTHERAPY (2003) (0)
- Expression and Prognostic Significance of Kit , Protein Kinase B , and Mitogen-activated Protein Kinase in Patients with Small Cell Lung Cancer 1 (2003) (0)
- Abstract 1998: Asparseprognostic gene signature for stage IB and II patients with completely resected non-small cell lung cancer (2010) (0)
- P-785 An audit of pophylactic cranial irradiation (PCI) in limited disease small cell lung cancer: Do we practice what we preach? (2005) (0)
- Dosimetric and Clinical Parameters Contributing to Esophagitis and Radiation Pneumonitis following Treatment for Small-cell Lung Carcinoma (2009) (0)
- MA25.11 Clinical and Molecular Predictors of Outcome in Patients with EGFR mutant NSCLC Brain Metastases treated with RT (2018) (0)
- Matrix metalloproteinase 2 (MMP2) polymorphism, Helicobacter pylori (HP) infection and esophageal adenocarcinoma (EA) risk (2007) (0)
- Abstract B194: Tivantinib in combination with erlotinib vs erlotinib alone for EGFR mutant NSCLC: Subgroup results from the phase 3 MARQUEE study (2015) (0)
- O-033PATIENTS WITH STAGE IIIA (N2) NON-SMALL-CELL LUNG CANCER SELECTED FOR NEOADJUVANT CHEMORADIATION AND SURGERY HAVE IMPROVED SURVIVAL COMPARED TO PATIENTS TREATED WITH DEFINITIVE CHEMORADIATION (2014) (0)
- Treatment Strategies for KRAS Mutated Non-small Cell Lung Cancer (2015) (0)
- P3.02c-076 Correlation of Neutrophil to Lymphocyte Ratio (NLR) with Clinical Benefit from Checkpoint Inhibitors in Advanced Lung Cancer: Topic: IT Biomarkers (2017) (0)
- 145 How to improve accrual to an important prospective randomized study: Prophylactic Cranial Irradiation (PCI) in Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) - RTOG 0214 (2005) (0)
- 790 Gender specific differences baseline of quality of life (QL) assessments in lung cancer patients: results from four National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) studies (1997) (0)
- Abstract 4210: Association of the 15q25 and 5p15 lung cancer susceptibility regions with gene expression in lung tumor tissue (2012) (0)
- RESULTS 1 a : In Patients with NSCLC , is There Sufficient Evidence to Recommend That Histologic Subtype Should Influence the Choice of Systemic Therapy ? (2011) (0)
- Role of the total mutation burden (TMB) and tumor-infiltrating lymphocytes (TILs) on the development of second primary cancer after complete resection of non-small cell lung cancer (NSCLC). (2020) (0)
- Genetic Polymorphisms Associated With Toxicity Are Associated With Overall Survival Following Curative Radiation for Non-Small Cell Lung Cancer (2014) (0)
- P1.04-23 Expression of Emerging Immunotherapy Targets in Early-Stage Squamous Lung Carcinoma (2018) (0)
- O-123 Hemithoracic radiotherapy for mesothelioma — challenges and solutions (2003) (0)
- 1347PTreatment beyond disease progression: ALK inhibitors in ALK-rearranged advanced NSCLC (2017) (0)
- Detection of EGFR mutations in cfDNA and development of resistance. (2018) (0)
- Response to Yamamoto et al. (2016) (0)
- Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer (NSCLC) patients. (2020) (0)
- Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer. (2023) (0)
- Chapter 17 – NON-SMALL-CELL LUNG CANCER: BLEOMYCIN PLUS ETOPOSIDE AND CISPLATIN (1985) (0)
- P3.16-07 The Impact of Clinical and Molecular Profile of Resected EGFR-Mutant Non-Small Cell Lung Cancer on the Risk of Developing Brain Metastases (2018) (0)
- Methylation profiling of EGFR mutant primary and metastatic lung cancer with brain metastasis. (2019) (0)
- 195 Retrospective review of delays in diagnostic work-up and treatment decision (2005) (0)
- Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial (2016) (0)
- EGFR mutations in NSCLC: Does ethnicity influence outcomes? (2015) (0)
- Modifiable metabolic markers c-peptide (C-PEP), highly sensitive c-reactive protein (hsCRP), leptin (LEP)] and lung cancer (LC) risk: A matched case-control study nested in the prostate, lung, colorectal and ovarian (PLCO) cancer screening study. (2015) (0)
- Highlights of the 2nd European Lung Cancer Conference (2010) (0)
- TGF-α and amphiregulin levels in non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib/placebo in the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) BR.21. (2016) (0)
- Genetic sequence variant (GSV) in TERT-CLPTM1L (5p15.33 locus) and survival in platinum-treated stage-IV non-small cell lung cancer (NSCLC). (2012) (0)
- P-625 Quantitative PCR validation of putative non-small cell lungcancer (NSCLC) prognostic marker genes derived from multiple published microarray databases and reports (2005) (0)
- Helicase-like transcription factor expression is associated with a poor prognosis in Non-Small-Cell Lung Cancer (NSCLC) (2018) (0)
- Outcomes in Patients With Stage III Non-Small Cell Lung Cancer Treated With Neoadjuvant Concurrent Chemotherapy and Radiation Therapy Followed by Surgical Resection (2015) (0)
- Clinical staging of small cell lung cancer: report of the International Association for the Study of Lung Cancer Staging Initiative, Small Cell Lung Cancer Subcommittee: E05-06 (2007) (0)
- Correlation of engraftment, mutation status, and response to chemotherapy in primary tumor xenograft models of NSCLC. (2010) (0)
- Costs of dacomitinib versus placebo in pretreated unselected patients (pts) with advanced NSCLC: CCTG BR.26 (2017) (0)
- P1.10-05 Tobacco Retail Availability and Tobacco Cessation Among Lung Cancer Survivors (2019) (0)
- Rapid expansion of M-MDSCs and association with high levels of plasma TSLP and primary resistance to PD-1 inhibitors in metastatic NSCLC. (2020) (0)
- P-336 Skp2 gene amplification in non-small cell lung carcinoma (2003) (0)
- P2.03b-089 CD1C in Lung Adenocarcinoma: Prognosis and Cellular Origin: Topic: Biomarkers (2017) (0)
- e conomic Analysis: r andomized Placebo- c ontrolled c linical t rial of e rlotinib in Advanced Non-Small c ell l ung c ancer (2010) (0)
- P1.02-036 An EGFR Tyrosine Kinase Inhibitor Sensitive Patient-Derived Lung Cancer Xenograft Model without Classical Sensitizing Mutations: Topic: Driver Genes in NSCLC, Resistance, and Other (2017) (0)
- 146 An audit of Prophylactic Cranial Irradiation (PCI) in limited disease small cell lung cancer: Do we practice what we preach? (2005) (0)
- P1.14-07 Genomic Profiling of Liquid Biopsies During 2nd/3rd Generation ALK Inhibitor Therapy to Identify Novel Mechanisms of Resistance (2019) (0)
- P2.06-011 Phase 2 Study of MM-121 plus Chemotherapy vs. Chemotherapy Alone in Heregulin-Positive, Locally Advanced or Metastatic NSCLC: Topic: Phase II + NK (2017) (0)
- Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk (2018) (0)
- P-152 Evaluation of novel prognostic markers detected by cDNA microarray in stage I–III non-small cell lung cancer by real-time RT-PCR (2003) (0)
- P2.03-04 Next Generation Sequencing in Lung Cancer Using the Oncomine Comprehensive Assay: The Canadian Publicly Funded Experience (2018) (0)
- Predictors of and longitudinal assessment of health utility scores in patients with small cell lung cancer using real-world data. (2020) (0)
- Preliminary results from phase Ib study of spartalizumab plus chemotherapy for advanced non-small cell lung cancer (NSCLC) (2019) (0)
- P2.01-015 Differentially Expressed microRNAs in Lung Adenocarcinoma Invert Effects of Copy Number Aberrations of Prognostic Genes: Topic: Analysis of RNA (2017) (0)
- P1.01-42 Real-World Evaluation of Tolerability in Older Adult Patients (≥75 years old) with EGFR-mutated NSCLC (2018) (0)
- Stratification and management of patients ineligible for lung cancer screening. (2021) (0)
- P1.01-30 Non-Small Cell Lung Cancer (NSCLC) Next Generation Sequencing (NGS): Integrating Genomic Sequencing into a Publicly Funded Health Care Model (2019) (0)
- P2.15-10 Determinants of Health Utility Scores (HUS) in Patients with ALK Rearranged Non-Small Cell Lung Cancer. (2018) (0)
- P-526 Phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer (NSCLC) (2005) (0)
- Genomic analysis of driver-negative lung adenocarcinoma (LA) in lifetime never smokers. (2020) (0)
- Abstract 02: Pan-cancer analysis of hotspot mutations in genes encoding the members of mitogen activated protein kinase (MAPK) and phosphoinosidtide-3 kinase (PI3K) pathways among smokers and non-smokers (2016) (0)
- IIIB.1 Adjuvant chemotherapy in elderly patients: an analysis of National Cancer Institute of Canada Clinical Trials Group and Intergroup JBR.10 (2006) (0)
- P2.14-62 Early, Subclinical SCLC Transformation in Patients with EGFR Mutant Lung Cancer Receiving Osimertinib, Detected Through Cell-Free DNA (2019) (0)
- 1070 Phase II trial with docetaxel in patients (PTS) with non small cell lung cancer (NSCLC) (1995) (0)
- Integrated analysis for two randomized phase III studies comparing Taxotere at 75 mg/m2 and 100 mg/m2 to control regimens in non-small cell lung cancer (NSCLC) patients previously treated with a platinum-based chemotherapy (2000) (0)
- 776 An economic analysis of the TAX 326 trial: a multicenter randomized study of docetaxel + cisplatin (DC) or docetaxel + carboplatin (DCb) vs. vinorelbine + cisplatin (VC) as first-line therapy in advanced non-small cell lung cancer (NSCLC) (2003) (0)
- The benefits of achieving stable disease in advanced lung cancer (2003) (0)
- Prospective R andomized T rial o f D ocetaxel V ersus B est Supportive C are i n P atients W ith N on-Small-Cell L ung Cancer P reviously T reated W ith P latinum-Based Chemotherapy (2011) (0)
- THE CANADIAN PHASE I-II TRIAL OF VACOP-B WITH FILGRASTIM FOR HIV RELATED NON HODGKIN'S LYMPHOMA (NHL): TOLERANCE AND DOSAGE STRATEGY. (1998) (0)
- 392 POSTER A phase I/II multicenter trial of BMS-690514, an ErbB-VEGFR inhibitor, in patients with advanced NSCLC who are erlotinib naive or previously treated with erlotinib (2008) (0)
- P-577 Prophylactic cranial irradiation (PCI) in locally advanced non-small cell lung cancer (RTOG 0214): How to improve accrual to an important prospective randomized study (2005) (0)
- 6550 POSTER A phase I study of concurrent pemetrexed/cisplatin/radiation for unresectable stage IIIA/B non-small cell lung cancer (2007) (0)
- Efforts in Lung Cancer : Focus on Early-Stage Non – Small-Cell Lung Cancer comprehensive review (2011) (0)
- MA14.06 Predictors of Financial Toxicity, an Under-Recognized Patient-Reported Outcome (2018) (0)
- Abstract 563: cfDNA-based analysis of minimal residual disease and T-cell receptor clonality as predictors of relapse in stage 3 NSCLC treated with chemoradiotherapy and durvalumab (2021) (0)
- Elderly patients with unresectable stage 3 NSCLC treated with definitive chemoradiation with or without durvalumab: Safety and outcomes. (2021) (0)
- Abstract 198: Two novel insertion polymorphisms of the BRM gene are associated with loss of BRM expression and lung cancer risk (2010) (0)
- Neurocognitive function testing and health related quality of life in stage IV lung cancer patients with and without brain metastases. (2017) (0)
- The value of defining molecular resistance in patients with progressive EGFR and ALK-driven lung cancer in a public system. (2021) (0)
- 1080 Phase I trial of gemcitabine (GEM) and cisplatin (CP) for non-small cell lung cancer (NSCLC) (1995) (0)
- P1.01-70 Dominant Circulating Myeloid Populations Are Associated with Poor Response in NSCLC Treated with 1st Line PD-1 Monotherapy (2019) (0)
- P1.13-36 Randomized Phase 2 Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer (2018) (0)
- P-507 Randomized trial to investigate the impact of a computer-generated quality of Life assessment program on treatment patterns for advanced non-small cell lung cancer patients (2005) (0)
- 607 NCIC CTG IND.196: Phase I Study of Foretinib (GSK1363089) and Erlotinib in Patients with Advanced Pretreated NSCLC (2012) (0)
- 120PSubgroup analysis of adenocarcinoma patients refractory to first-line chemotherapy from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non–small cell lung cancer (NSCLC) (2017) (0)
- Survival Impact of Prophylactic Cranial Irradiation in Limited-stage Small-cell Lung Cancer (2009) (0)
- P14.24 Evolution of TCR Clonality during Chemoradiation and Durvalumab as Predictors of Survival in Stage 3 NSCLC (2021) (0)
- P2.03b-077 EGFR/ALK+ Patient-Derived Xenografts from Advanced NSCLC for TKI Drug Selection & Resistance Development: The REAL-PDX Study: Topic: Biomarkers (2017) (0)
- Prognostic and predictive effects of a gene expression signature for NRF2 pathway activation in lung squamous cell carcinoma (SqCC). (2013) (0)
- Performance of a prognostic genomic signature for early-stage NSCLC in matched fresh frozen and RNA-stabilized tissue. (2013) (0)
- Myeloid immunosuppressive state as a predictor of rapidly progressive phenotype and poor survival in advanced non-small cell lung cancer (NSCLC) patients treated with PD-1/PD-L1 inhibitors. (2019) (0)
- P2.03-11 Impact of Ethnicity on Outcome in Never Smokers with EGFR and ALK Wildtype (EGFR/ALK-Wildtype) Lung Adenocarcinomas (2019) (0)
- A phase I/II study of concurrent pemetrexed/cisplatin/radiation in stage IIIa/b non-small cell lung cancer: P2-165 (2007) (0)
- L-BLP25 treatment for advanced non-small cell lung cancer (NSCLC): Safety data from a phase IIb trial compared with an integrated safety analysis (ISA). (2010) (0)
- Predicting response to second-line treatment with TaxotereR (Tax) in patients with non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy (2000) (0)
- Clinical Trial Protocol (2011) (0)
- Relationship Between EGFR Expression Level, EGFR Mutation Status and the Efficacy of Chemotherapy Plus Cetuximab in Flex Study Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) (2012) (0)
- Abstract CT206: A phase I study of binimetinib, a MEK inhibitor, in combination with pembrolizumab in patients with advanced non-small cell lung cancer (NSCLC) (2023) (0)
- Real-world EQ5D health utility values for metastatic lung cancer patients by molecular alteration and response to therapy. (2016) (0)
- 1312PTHE RELATIONSHIP BETWEEN EGFR AND KRAS MUTATION STATUS AND OVERALL SURVIVAL (OS) IN THE NCIC CTG BR.26 RANDOMIZED TRIAL OF DACOMITINIB (D) VERSUS PLACEBO (P) IN PATIENTS WITH PREVIOUSLY TREATED NON SMALL CELL LUNG CANCER (NSCLC). (2014) (0)
- O-118 Optmizing cancer treatment decision-making: Pilot study of a treatment decision aid in stage IV non-small cell lung cancer (2003) (0)
- OA 15.01 Lung Cancer Screening: Participant Selection by Risk Model – the Pan-Canadian Study (2017) (0)
- Longitudinal Assessment of Health Utility Scores, Symptoms and Toxicities in Patients with Small Cell Lung Cancer Using Real World Data. (2021) (0)
- MA27.03 Multi-Omic Characterization of TKI-Treated Drug-Tolerant Cell Population in an EGFR-Mutated NSCLC Primary-Derived Xenograft (2018) (0)
- BSCI-26. COMPARATIVE METHYLATION PROFILING OF EGFR MUTANT LUNG ADENOCARCINOMA AND PAIRED BRAIN METASTASIS (2019) (0)
- Anticoagulation and bleeding: A pooled analysis of lung cancer trials of the National Cancer Institute of Canada Clinical Trials Group (2008) (0)
- Chemotherapy in Nonsmall Cell ung Cancer : A Systematic Review (2006) (0)
- P1.13-15 Detection of EGFR Mutations in cfDNA and Development of Resistance (2018) (0)
- Discussion: Lung cancer (1996) (0)
- Feasibility of collecting routine information for clinical and research purposes via electronic format questionnaire. (2017) (0)
- 168OPOOLED ANALYSIS OF THE PROGNOSTIC AND PREDICTIVE VALUE OF KRAS MUTATION STATUS AND MUTATION SUBTYPE IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH EGFR TKIS (E-TKI). (2014) (0)
- O-036 Superior sulcus (pancoast) tumors treated with combinedtri-Modality therapy: Is there a role for prophylactic cranial irradiation? (2005) (0)
- Abstract 5069: Genomic profiles of primary non-small cell lung cancer (NSCLC) xenograft tumors identify distinct gene signatures associated with histological subtypes (2012) (0)
- Clinical impact of EGFR mutation fraction and tumor cellularity in EGFR mutation positive NSCLC. (2013) (0)
- Chemotherapy in the Elderly: Standard Chemotherapy or Specific Regimens? (2013) (0)
- Single nucleotide polymorphisms (SNPs) of the platinum pharmacogenetic and VEGF pathways: Association with survival of platinum-treated stage IV non-small cell lung cancer (NSCLC) patients. (2012) (0)
- Chapter 6 Systemic therapy for recurrent NSCLC, efficacy, and toxicity (2011) (0)
- MA 13.02 Comprehensive Genetic Analysis Related to PD-L1 Expression in Early-stage Lung Squamous Cell Carcinoma (2017) (0)
- BIOM-02. IDENTIFYING MGMT ALTERATIONS AS BIOMARKERS OF SURVIVAL IN LUNG ADENOCARCINOMA WITH BRAIN METASTASES (2020) (0)
- An Analysis of the Influence of Sex and Histology on Outcomes in Non-Small Cell Lung Cancer (2009) (0)
- Changes in Body Composition in Patients with Small-Cell Lung Cancer (2020) (0)
- IL1 Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) : Current Status and Future Directions (2007) (0)
- P-643 Stability of RNA and phosphorylated proteins in surgically resected tumor specimens (2003) (0)
- CMET-30. COMPREHENSIVE METHYLOME ANALYSIS OF EGFR-MUTANT PRIMARY LUNG ADENOCARCINOMA AND MATCHED BRAIN METASTASIS (2019) (0)
- Gemcitabine Plus Vinore lb ine Compared With Cisplat in Plus Vinore lb ine or Cisplat in Plus Gemci tabine for Advanced Non – Smal l-Cel l Lung Cancer : A Phase III Tria (2003) (0)
- PR01.07 Predicting Changes in Lung Cancer Risk in the At-Risk Screen Ineligible Population (2021) (0)
- Treatment of the elderly when cure is the goal: The influence of age on treatment selection and efficacy for stage III non-small cell lung cancer (NSCLC). (2010) (0)
- mproved results of induction chemoradiation before urgical intervention for selected patients with stage IIA-N 2 non – small cell lung cancer arl (2007) (0)
- P1.06-039 Retrospective Study of the Incidence and Outcomes from Lung Cancer That Developed Following a Solid Organ Transplant: Topic: Advanced General (2017) (0)
- Stereotactic body radiotherapy (SBRT) and medical inoperability of early stage non-small cell lung cancer. (2006) (0)
This paper list is powered by the following services:
Other Resources About Frances Alice Shepherd
What Schools Are Affiliated With Frances Alice Shepherd?
Frances Alice Shepherd is affiliated with the following schools:
